Anita Rath Sørensen, Elisabeth Bendstrup, Anders Løkke, Ingrid Louise Titlestad, Jens Ulrik Stæhr Jensen, Laura Hohwu Thomsen, Nassim Bazeghi Roberts, Pia Holland Gjørup, Saher Shaker, Svend Gundestrup, Torgny Rostrup Wilcke, Ulla Møller Weinreich, Kristoffer Marså:
Treatment limitations or discontinuation in patients with benign pulmonary diseases
Ugeskr Læger 2018;180:V04180270
The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients‘ and informal caregivers‘ wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient’s wishes, the disease stage and progression and potential reversible components.